Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CBL 137

Next Previous
X
Search
Drug Profile

CBL 137

Alternative Names: CBL-0137; CBLC-137; Curaxin CBL0137

Latest Information Update: 02 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cleveland BioLabs
  • Developer Incuron; National Cancer Institute (USA); Roswell Park Cancer Institute; Statera BioPharma
  • Class Antineoplastics; Carbazoles; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA intercalators; NF-kappa B inhibitors; SSRP1 protein inhibitors; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Diffuse intrinsic pontine glioma; Lymphoma; Osteosarcoma; Solid tumours
  • No development reported Haematological malignancies; Malignant melanoma; Neuroblastoma; Sarcoma

Most Recent Events

  • 25 Mar 2024 Roswell Park Cancer Institute and National Cancer Institute (NCI) terminates a phase I trial of Melanoma and Sarcoma (Recurrent disease, Late-stage disease, Advanced stage) in USA (Intra-arterial, Infusion), due to low accural (NCT03727789)
  • 28 Oct 2023 No recent reports of development identified for preclinical development in Neuroblastoma in USA (Parenteral)
  • 28 Aug 2022 No recent reports of development identified for phase-I development in Malignant-melanoma(Late-stage disease, Second-line therapy or greater) in USA (Intra-arterial)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top